...
search icon
acrs-img

Aclaris Therapeutics Inc, Common Stock

ACRS

NSQ

$1.53

-$0.03

(-1.92%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$158.09M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
737.32K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.42
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.99 L
$5.17 H
$1.53

About Aclaris Therapeutics Inc, Common Stock

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameACRSSectorS&P500
1-Week Return4.79%0.35%0.61%
1-Month Return19.53%-0.91%6.14%
3-Month Return-15.93%-10.83%3.5%
6-Month Return-61.17%-7.74%-2.46%
1-Year Return48.54%-9%10.92%
3-Year Return-89.63%2.52%44.02%
5-Year Return5.52%28.09%83.43%
10-Year Return-86.15%79.95%185.22%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue6.48M6.76M29.75M31.25M18.72M[{"date":"2020-12-31","value":20.74,"profit":true},{"date":"2021-12-31","value":21.64,"profit":true},{"date":"2022-12-31","value":95.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":59.91,"profit":true}]
Cost of Revenue5.13M4.71M11.96M18.08M2.79M[{"date":"2020-12-31","value":28.39,"profit":true},{"date":"2021-12-31","value":26.07,"profit":true},{"date":"2022-12-31","value":66.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":15.44,"profit":true}]
Gross Profit1.35M2.05M17.79M13.17M3.46M[{"date":"2020-12-31","value":7.58,"profit":true},{"date":"2021-12-31","value":11.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.01,"profit":true},{"date":"2024-12-31","value":19.46,"profit":true}]
Gross Margin20.81%30.29%59.80%42.14%18.49%[{"date":"2020-12-31","value":34.8,"profit":true},{"date":"2021-12-31","value":50.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.47,"profit":true},{"date":"2024-12-31","value":30.93,"profit":true}]
Operating Expenses52.26M67.43M102.95M110.53M157.86M[{"date":"2020-12-31","value":33.11,"profit":true},{"date":"2021-12-31","value":42.72,"profit":true},{"date":"2022-12-31","value":65.21,"profit":true},{"date":"2023-12-31","value":70.01,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(50.91M)(65.38M)(85.15M)(97.36M)(141.93M)[{"date":"2020-12-31","value":-5091200000,"profit":false},{"date":"2021-12-31","value":-6538400000,"profit":false},{"date":"2022-12-31","value":-8515400000,"profit":false},{"date":"2023-12-31","value":-9735700000,"profit":false},{"date":"2024-12-31","value":-14193200000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(51.34M)(90.86M)(86.91M)(88.85M)(132.06M)[{"date":"2020-12-31","value":-5133600000,"profit":false},{"date":"2021-12-31","value":-9086500000,"profit":false},{"date":"2022-12-31","value":-8690800000,"profit":false},{"date":"2023-12-31","value":-8884800000,"profit":false},{"date":"2024-12-31","value":-13206500000,"profit":false}]
Income Taxes(182.00K)23.42M1.75M(367.00K)-[{"date":"2020-12-31","value":-0.78,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":7.49,"profit":true},{"date":"2023-12-31","value":-1.57,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(51.15M)(90.86M)(86.91M)(88.48M)(132.06M)[{"date":"2020-12-31","value":-5115400000,"profit":false},{"date":"2021-12-31","value":-9086500000,"profit":false},{"date":"2022-12-31","value":-8690800000,"profit":false},{"date":"2023-12-31","value":-8848100000,"profit":false},{"date":"2024-12-31","value":-13206500000,"profit":false}]
Income From Discontinued Operations139.00K----[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(51.15M)(114.28M)(88.66M)(88.48M)(132.06M)[{"date":"2020-12-31","value":-5115400000,"profit":false},{"date":"2021-12-31","value":-11428100000,"profit":false},{"date":"2022-12-31","value":-8866200000,"profit":false},{"date":"2023-12-31","value":-8848100000,"profit":false},{"date":"2024-12-31","value":-13206500000,"profit":false}]
EPS (Diluted)(1.20)(1.63)(1.33)(1.25)(1.51)[{"date":"2020-12-31","value":-120,"profit":false},{"date":"2021-12-31","value":-163,"profit":false},{"date":"2022-12-31","value":-133,"profit":false},{"date":"2023-12-31","value":-125,"profit":false},{"date":"2024-12-31","value":-151,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ACRS
Cash Ratio 4.90
Current Ratio 5.06

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ACRS
ROA (LTM) -18.20%
ROE (LTM) -91.03%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ACRS
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.73

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ACRS
Trailing PE NM
Forward PE NM
P/S (TTM) 9.32
P/B 1.15
Price/FCF NM
EV/R 2.64
EV/Ebitda 0.28
PEG NM

FAQs

What is Aclaris Therapeutics Inc share price today?

Aclaris Therapeutics Inc (ACRS) share price today is $1.53

Can Indians buy Aclaris Therapeutics Inc shares?

Yes, Indians can buy shares of Aclaris Therapeutics Inc (ACRS) on Vested. To buy Aclaris Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACRS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aclaris Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Aclaris Therapeutics Inc (ACRS) via the Vested app. You can start investing in Aclaris Therapeutics Inc (ACRS) with a minimum investment of $1.

How to invest in Aclaris Therapeutics Inc shares from India?

You can invest in shares of Aclaris Therapeutics Inc (ACRS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ACRS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aclaris Therapeutics Inc shares
What is Aclaris Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Aclaris Therapeutics Inc (ACRS) is $5.17. The 52-week low price of Aclaris Therapeutics Inc (ACRS) is $0.99.

What is Aclaris Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aclaris Therapeutics Inc (ACRS) is 1.15

What is the Market Cap of Aclaris Therapeutics Inc?

The market capitalization of Aclaris Therapeutics Inc (ACRS) is $158.09M

What is Aclaris Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Aclaris Therapeutics Inc is ACRS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top